Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.
暂无分享,去创建一个
Y. Shin | Yoon-Koo Kang | H. Lee | J. Shim | M. Ryu | Min-Joo Kim | K. Kim | Y. Lim | B. Ryoo | G. Choi
[1] Joong-Won Park,et al. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. , 2012, Journal of hepatology.
[2] R. Stauber,et al. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. , 2012, Radiology.
[3] H. Chang,et al. Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma , 2012, Oncology.
[4] Y. Shin,et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. , 2012, Radiology.
[5] Y. Rolland,et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma , 2012, Cancer.
[6] G. Abou-Alfa. TACE and sorafenib: a good marriage? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] T. Pawlik,et al. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Gary King,et al. MatchIt: Nonparametric Preprocessing for Parametric Causal Inference , 2011 .
[9] H. Lee,et al. Applicability of the BCLC staging system to patients with hepatocellular carcinoma in Korea: analysis at a single center with a liver transplant center , 2011, The Korean journal of hepatology.
[10] J. Bruix,et al. Management of hepatocellular carcinoma: An update , 2011, Hepatology.
[11] Y. Kim,et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. , 2011, Radiology.
[12] K. Sung,et al. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: Does transarterial chemoembolization improve survival in these patients? , 2011, Journal of gastroenterology and hepatology.
[13] W. Lau,et al. Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Prospective Comparative Study , 2011, Annals of Surgical Oncology.
[14] Riccardo Lencioni,et al. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.
[15] T. Vogl,et al. Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study , 2009, CardioVascular and Interventional Radiology.
[16] K. Sung,et al. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion , 2009, Journal of gastroenterology and hepatology.
[17] Yoon-Koo Kang,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.
[18] Joong-Won Park,et al. Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area , 2009, Journal of Cancer Research and Clinical Oncology.
[19] Dieter Häussinger,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[20] Tae Hyun Kim,et al. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus–endemic area , 2008, Journal of gastroenterology and hepatology.
[21] K. Chayama,et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. , 2007, World journal of gastroenterology.
[22] J. Robins,et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. , 2006, American journal of epidemiology.
[23] C. Georgiades,et al. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. , 2005, Journal of vascular and interventional radiology : JVIR.
[24] John Wong,et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma , 2002, Hepatology.
[25] R. Molinari,et al. Prognostic features and survival of hepatocellular carcinoma in Italy: impact of stage of disease. , 2001, European journal of cancer.
[26] J. Robins,et al. Marginal Structural Models and Causal Inference in Epidemiology , 2000, Epidemiology.
[27] Jae Hyung Park,et al. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction , 1997, Cancer.
[28] Y. I. Kim,et al. Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma: CT and pathologic findings. , 1992, Radiology.
[29] I. Tannock,et al. Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.